8 mg implantat

DRUG3 trials

Sponsors

UZ Leuven, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Conditions

Early Breast CancerMetastatic hormone-sensitive prostate cancer with high tumor loadOligorecurrent hormone-sensitive prostate cancer patients

Phase 3

Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial.

RecruitingCTIS2022-502373-42-00

UZ LeuvenOligorecurrent hormone-sensitive prostate cancer patients

Start: 2022-04-25Target: 873Updated: 2025-03-31

One multicenter, randomized, open, phase III clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of metastatic hormone-sensitive prostate cancer with high tumor load.

Not yet recruitingCTIS2024-515194-10-00

Jiangsu Hengrui Pharmaceuticals Co. Ltd.Metastatic hormone-sensitive prostate cancer with high tumor load

Target: 63Updated: 2024-12-09

Phase 4

Impact of EXercise on quality of life of early breast cancer patients on treatment with adjuvant Aromatase Inhibitors with or without CDK4/6 inhibitors. "The EX-AI study"

Not yet recruitingCTIS2025-522848-40-00

Fundacion Grupo Espanol De Investigacion En Cancer De MamaEarly Breast Cancer

Target: 74Updated: 2025-12-29